One intervention in ORIGIN compared the effect of insulin glargine to standard care on major adverse cardiovascular (CV) outcomes in 12,537 adults 50 years of age with
Novel Therapeutics in Diabetic Gastroparesis An effective, safe prokinetic is the goal for patients with gastroparesis, and medications in development, including ghrelin agonists and new generation 5-HT4 agonists, hold promise
The frequency and severity of diarrhea typically correlate with dose escalation
The phase 2 trial showed 22.8% average weight loss at 48 weeks with the 8mg dose, only 1.4 percentage points less than the 12mg dose
At Skippack Pharmacy, your health is our priority
This rapid rate of adoption has resulted in record profits for pharmaceutical companies like Novo Nordisk and Eli Lilly